Findings showed that the rising prevalence of cancer and greater patient access to treatments in pharmerging nations continues to grow and now accounts for 13 percent of the market. Targeted therapies, which take aim at specific drivers of cancer, now account for almost half of total spending. Murray Aitken, senior vice president at IMS Health said, "The increased prevalence of most cancers, earlier treatment initiation, new medicines and improved outcomes are all contributing to the greater demand for oncology therapeutics around the world."
Forty-five new drugs for cancer hit the market between 2010 and 2014, including 10 last year alone. Two of those are so-called immunotherapies -- a hot new class that harnesses the immune system to fight cancer and cost around 12,500 dollars a month. Innovative therapeutic classes, combination therapies and the use of biomarkers will change the landscape over the next several years, holding out the promise of substantial improvements in survival with lower toxicity for cancer patients, he added.
The study is a comprehensive review and updated perspective on the current and future clinical landscape, marketplace dynamics for oncology-related pharmaceuticals, and patient access to medicines and their value.